Novartis plans to seek approval for CAR-T in slow-growing lymphoma after Phase II success

The company said the study of Kymriah in follicular lymphoma met its primary endpoint, though it did not disclose the trial data. It plans to submit approval applications to the FDA and EMA next year.

Fresh off the heels of the Food and Drug Administration approval of the third CAR-T cell therapy, a company that markets one of the approved CAR-Ts has said a clinical trial of its product was successful.

Basel, Switzerland-based Novartis said Tuesday that the Phase II ELARA study of Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma had met its primary endpoint of complete response rate. Although the did not disclose the actual data, it said it plans to submit them to the FDA and European Medicines Agency next year, with plans to present them at an upcoming medical meeting.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Kymriah was the first CAR-T therapy to reach the market, when the FDA approved it in 2017 for acute lymphoblastic leukemia in children and young adults. Kite Pharma – now owned by Gilead Sciences – won FDA approval for its CAR-T, Yescarta (axicabtagene ciloleucel) for diffuse large B-cell lymphoma soon thereafter. Kymriah also won approval for DLBCL, in May 2018. And last month, the FDA approved the third CAR-T, Gilead’s Tecartus (brexucabtagene autoleucel), for mantle cell lymphoma. All three CAR-Ts target CD19, an antigen widely expressed on the surfaces of ALL and B-NHL cells.

Like MCL, follicular lymphoma is an indolent – or slow-growing – form of B-cell non-Hodgkin’s lymphoma and accounts for 22% of lymphoma cases. Unlike DLBCL, its fast-growing and much more common cousin, it is considered incurable and repeatedly relapses and remits, with patients receiving a median five lines of treatment and as many as 12.

“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said John Tsai, Novartis’ chief medical officer, in a statement.

Numerous other CAR-T cell therapies are also in development, with some likely to win regulatory approval in the near future. These include Bristol-Myers Squibb’s lisocabtagene maraleucel, a CD19-targeting CAR-T it is developing for non-Hodgkin’s lymphoma, as well as idecabtagene vicleucel, which BMS is developing with bluebird bio and is a CAR-T that targets the BCMA antigen in patients with multiple myeloma. BMS and bluebird refiled their approval application for the CAR-T last week.

Photo: CGToolbox, Getty Images